Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice
Alba Matas‐Céspedes(AstraZeneca (United Kingdom)), Richard Stebbings(University of Hertfordshire)
Cited by 2
Related Papers
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 <sup>+</sup> effector memory T‐cells
|British Journal of Pharmacology|2010|290